Patents by Inventor Iriny Botrous

Iriny Botrous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12006325
    Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: June 11, 2024
    Assignee: Dart NeuroScience, LLC
    Inventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
  • Publication number: 20240182494
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, A, E1, E2, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: December 1, 2023
    Publication date: June 6, 2024
    Inventors: Svitlana KULYK, Shawn WRIGHT, Joseph DENNIS, Wallace DERRICOTTE, Iriny BOTROUS, Laurent GOMEZ
  • Publication number: 20240132521
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, A, E1, E2, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: August 22, 2023
    Publication date: April 25, 2024
    Inventors: Svitlana KULYK, Shawn WRIGHT, Joseph DENNIS, Wallace DERRICOTTE, Iriny BOTROUS, Laurent GOMEZ
  • Publication number: 20240083861
    Abstract: Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 14, 2024
    Inventors: Andrew R. Hudson, Steven P. Govek, Johnny Y. Nagasawa, Iriny Botrous, Nicholas D. Smith, Karensa L. Fasanya
  • Publication number: 20240034736
    Abstract: Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.
    Type: Application
    Filed: September 29, 2021
    Publication date: February 1, 2024
    Inventors: Andrew R. Hudson, Steven P. Govek, Johnny Y. Nagasawa, Iriny Botrous, Nicholas D. Smith, Karensa L. Fasanya
  • Publication number: 20230295178
    Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.
    Type: Application
    Filed: September 2, 2022
    Publication date: September 21, 2023
    Inventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
  • Publication number: 20230102554
    Abstract: Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, tautomer, isotope, or salt thereof, wherein A, X, R3, R5, R6, R7, R8, Y2, Y4, Y6, Y7, Y8, Y9, m, and n are as defined herein. Such compounds inhibit tyrosine kinase receptors, particularly the platelet derived growth factor receptor-alpha (PDGFR-?) and/or the platelet derived growth factor receptor-beta (PDGFR-?). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Application
    Filed: June 26, 2020
    Publication date: March 30, 2023
    Inventors: Luis Lopez, Craig Coburn, Martin W. Rowbottom, Iriny Botrous, Michelle Kasem
  • Patent number: 11434247
    Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: September 6, 2022
    Assignee: Dart Neuroscience LLC
    Inventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
  • Publication number: 20220002309
    Abstract: Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
    Type: Application
    Filed: October 23, 2019
    Publication date: January 6, 2022
    Inventors: Nicholas D. SMITH, Andrew R. HUDSON, Mi CHEN, Johnny Y. NAGASAWA, Iriny BOTROUS
  • Publication number: 20200181104
    Abstract: Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Inventors: Nicholas D. Smith, Andrew R. Hudson, Mi Chen, Johnny Y. Nagasawa, Iriny Botrous
  • Publication number: 20190177327
    Abstract: A chemical entity of Formula (I) or Formula (II): wherein Ra, Rb, Re, and Rf have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.
    Type: Application
    Filed: October 12, 2018
    Publication date: June 13, 2019
    Inventors: Brett Bookser, Iriny Botrous, Bryan Branstetter, Brian Dyck, Michael Weinhouse
  • Patent number: 8999981
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: April 7, 2015
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • Publication number: 20120108588
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 3, 2012
    Applicant: Pfizer, Inc.
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • Patent number: 8114871
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: February 14, 2012
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • Patent number: 8106197
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: January 31, 2012
    Assignee: Pfizer Inc.
    Inventors: Jingrong Jean Cui, Dilip Bhumralkar, Iriny Botrous, Ji Yu Chu, Lee A. Funk, Cathleen Elizabeth Hanau, G. Davis Harris, Lei Jia, Joanne Johnson, Stephen A. Kolodziej, Pei-Pei Kung, Xiaoyuan (Sharon) Li, Jason (Qishen) Lin, Jerry Jialun Meng, Mitchell David Nambu, Christopher G. Nelson, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • Publication number: 20100249128
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Application
    Filed: April 10, 2008
    Publication date: September 30, 2010
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • Patent number: 7250417
    Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: July 31, 2007
    Assignee: Sugen Inc.
    Inventors: Jingrong Cui, Iriny Botrous
  • Patent number: 7230098
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: June 12, 2007
    Assignee: Sugen, Inc.
    Inventors: Jingrong Jean Cui, Dilip Bhumralkar, Iriny Botrous, Ji Yu Chu, Lee A. Funk, Cathleen Elizabeth Hanau, G. Davis Harris, Lei Jia, Joanne Johnson, Stephen A. Kolodziej, Pei-Pei Kung, Xiaoyuan (Sharon) Li, Jason (Qishen) Lin, Jerry Jialun Meng, Mitchell David Nambu, Christopher G. Nelson, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • Publication number: 20070072874
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
    Type: Application
    Filed: November 14, 2006
    Publication date: March 29, 2007
    Inventors: Jingrong Cui, Dilip Bhumralkar, Iriny Botrous, Ji Chu, Lee Funk, Cathleen Hanau, G. Harris, Lei Jia, Joanne Johnson, Stephen Kolodziej, Pei-Pei Kung, Xiaoyuan Li, Jason Lin, Jerry Meng, Mitchell Nambu, Christopher Nelson, Mason Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • Publication number: 20050107391
    Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
    Type: Application
    Filed: June 25, 2004
    Publication date: May 19, 2005
    Inventors: Jingrong Cui, Iriny Botrous